Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden · Delayed Price · Currency is SEK 11.70
+0.05 (0.43%)
May 21, 2026, 1:05 PM CET
Xbrane Biopharma AB Market Cap
Xbrane Biopharma AB has a market cap or net worth of 240.05 million as of May 21, 2026. Its market cap has decreased by -19.66% in one year.
Market Cap
240.05M
Enterprise Value
230.18M
Revenue
76.45M
Ranking
n/a
PE Ratio
2.26
Stock Price
11.70
Market Cap Chart
Since February 3, 2016, Xbrane Biopharma AB's market cap has increased from 131.05M to 240.05M, an increase of 83.17%. That is a compound annual growth rate of 6.05%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 20, 2026 | 240.05M | 14.22% |
| Dec 30, 2025 | 210.17M | -14.54% |
| Dec 30, 2024 | 245.94M | -17.28% |
| Dec 29, 2023 | 297.31M | -86.83% |
| Dec 30, 2022 | 2.26B | -13.94% |
| Dec 30, 2021 | 2.62B | 58.03% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Sprint Bioscience AB | 361.92M |
| Mendus AB | 346.01M |
| Isofol Medical AB | 244.54M |
| Xintela AB | 215.32M |
| Active Biotech AB | 206.93M |
| Initiator Pharma | 197.14M |
| Diamyd Medical AB | 187.53M |
| Nanologica AB | 164.38M |